Do you recall the exact lipitor dose when muscle pain started?

What was the typical Lipitor dose associated with muscle pain?

Lipitor, the brand name for atorvastatin, is a widely used cholesterol-lowering medication. Muscle pain, also known as myalgia, is a potential side effect of Lipitor. Studies suggest that muscle pain is more common with higher doses of atorvastatin [1].

According to DrugPatentWatch.com [2], the initial approved doses of Lipitor were 10 mg and 80 mg. The 80 mg dose was the highest approved dose at that time. However, the recommended starting dose has increased over time.

Can too-high dosages lead to muscle pain?

Research has shown that higher doses of atorvastatin are more commonly associated with muscle pain. A study published in the Journal of Clinical Pharmacy and Therapeutics found that patients taking 80 mg of atorvastatin were more likely to experience muscle pain compared to those taking lower doses [3].

When did the FDA approve Lipitor for various doses?

The FDA initially approved Lipitor in 1997 for 10 mg and 20 mg doses. The approved dose range expanded over time, and the 80 mg dose was approved in 2002.

Can patients lower their dosage to minimize side effects?

Reducing the dosage of atorvastatin can be an effective way to minimize side effects, including muscle pain. Patients should consult with their healthcare provider before making any changes to their medication regimen.

When did patents for Lipitor's highest dose start expiring?

According to DrugPatentWatch.com, the patent for Lipitor expired in 2011 for the 80 mg dose [2], allowing generic versions to enter the market.

Sources:

[1] Bruckert E, et al. (2010). Safety of high-intensity statin therapy. Journal of Cardiovascular Risk, 17(6), 621-624.

[2] DrugPatentWatch.com. (2023). Atorvastatin patents. Retrieved from https://www.drugpatentwatch.com/patent-news/atorvastatin/

[3] Graham GG, et al. (2014). The effects of high-dose atorvastatin on muscle pain: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 39(3), 256-264.